Empagliflozin in patients with chronic kidney disease
In this trial involving patients with chronic kidney disease, empagliflozin resulted in a lower risk of disease progression or death from cardiovascular causes than placebo.
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
January 12, 2023
|
| In: |
The New England journal of medicine
Year: 2023, Volume: 388, Issue: 2, Pages: 117-127 |
| ISSN: | 1533-4406 |
| DOI: | 10.1056/NEJMoa2204233 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1056/NEJMoa2204233 Verlag, kostenfrei, Volltext: https://www.nejm.org/doi/full/10.1056/NEJMoa2204233 
|
| Author Notes: | The EMPA-KIDNEY Collaborative Group |
| Summary: | In this trial involving patients with chronic kidney disease, empagliflozin resulted in a lower risk of disease progression or death from cardiovascular causes than placebo. |
|---|---|
| Item Description: | Online veröffentlicht: 4. November 2022 Mitglieder der EMPA-KIDNEY Collaborative Group: W.G. Herrington, N. Staplin, C. Wanner, J.B. Green, S.J. Hauske, J.R. Emberson, D. Preiss, P. Judge, K.J. Mayne, S.Y.A. Ng, E. Sammons, D. Zhu, M. Hill, W. Stevens, K. Wallendszus, S. Brenner, A.K. Cheung, Z.-H. Liu, J. Li, L.S. Hooi, W. Liu, T. Kadowaki, M. Nangaku, A. Levin, D. Cherney, A.P. Maggioni, R. Pontremoli, R. Deo, S. Goto, X. Rossello, K.R. Tuttle, D. Steubl, M. Petrini, D. Massey, J. Eilbracht, M. Brueckmann, M.J. Landray, C. Baigent, and R. Haynes Gesehen am 01.07.2024 |
| Physical Description: | Online Resource |
| ISSN: | 1533-4406 |
| DOI: | 10.1056/NEJMoa2204233 |